Atazanavir and Cobicistat
1 NDC across 1 manufacturer|0 Generic,1 Brand
▸ More about this market▾ Less
Atazanavir and Cobicistat is available as 1 NDC from 1 manufacturer (0 generic, 1 brand), with NADAC prices from $52.05 to $52.05 per EA. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
1
0G / 1B
Manufacturers
1
competing in market
Price Spread
$52.05 – $52.05
per EA
7d Activity
avg +0.1% WoW · of 1 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
E.R. Squibb & Sons, L.L.C. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Cytochrome P450 3A Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing ATAZANAVIR AND COBICISTAT
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
EVOTAZ 300 MG-150 MG TABLET | $52.0479 per EA | +0.06% |
Frequently Asked Questions
How many Atazanavir and Cobicistat products are on the market?
The Atazanavir and Cobicistat drug market contains 1 NDC from 1 manufacturer — 0 generic and 1 brand product.
What is the price range for Atazanavir and Cobicistat?
NADAC reference prices for Atazanavir and Cobicistat range from $52.0479 to $52.0479 per EA.
Which manufacturers make Atazanavir and Cobicistat?
1 manufacturer lists Atazanavir and Cobicistat in NADAC. Ranked by number of NDCs, the largest are E.R. Squibb & Sons, L.L.C. (1).
How has the price of Atazanavir and Cobicistat changed recently?
Over the past 7 days, 2 Atazanavir and Cobicistat NDCs rose and 0 fell, with a market-wide average change of +0.1%.